Acadia Pharmaceuticals | ACAD - Operating Profit

Stock Price
23.99
Daily Change
-0.34 -1.40%
Monthly
-10.35%
Yearly
20.25%
Q1 Forecast
23.25

Acadia Pharmaceuticals reported $35.76M in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
Acadia Pharmaceuticals USD 35.76M 3.38M Sep/2025
ALKERMES USD 89.08M 3.9M Sep/2025
Alnylam Pharmaceuticals USD 29.4M 59.36M Dec/2025
Biogen USD 659.6M 192.2M Sep/2025
BioMarin Pharmaceutical USD -31.69M 308.58M Sep/2025
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Cara Therapeutics USD -2.39M 3.49M Mar/2025
Corcept Therapeutics USD 10.22M 16.46M Sep/2025
Cytokinetics USD -166.76M 55.25M Sep/2025
Eisai JPY 20.03B 6.36B Dec/2025
Eli Lilly USD 8.99B 599.9M Dec/2025
Incyte USD 383.88M 47.43M Dec/2025
J&J USD 5.59B 1.81B Dec/2025
Moderna USD -857M 597M Dec/2025
Neurocrine Biosciences USD 227.9M 11.4M Dec/2025
Pfizer USD 4.65B 3.99B Dec/2025
Prothena USD -39.76M 12.25M Sep/2025
PTC Therapeutics USD -81.62M 85.11M Dec/2025
Sarepta Therapeutics USD -62.88M 178.46M Sep/2025
Ultragenyx Pharmaceutical USD -114M 56.89M Dec/2025
Vanda Pharmaceuticals USD -40.66M 29.66M Dec/2024
Vertex Pharmaceuticals USD 1.26B 24.5M Dec/2025